TW200716202A - Pediatric formulation of topiramate - Google Patents

Pediatric formulation of topiramate

Info

Publication number
TW200716202A
TW200716202A TW095118344A TW95118344A TW200716202A TW 200716202 A TW200716202 A TW 200716202A TW 095118344 A TW095118344 A TW 095118344A TW 95118344 A TW95118344 A TW 95118344A TW 200716202 A TW200716202 A TW 200716202A
Authority
TW
Taiwan
Prior art keywords
composition
topiramate
liquid
pediatric formulation
preparing
Prior art date
Application number
TW095118344A
Other languages
English (en)
Chinese (zh)
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Roger Carolus Augusta Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35045349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200716202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200716202A publication Critical patent/TW200716202A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
TW095118344A 2005-05-25 2006-05-24 Pediatric formulation of topiramate TW200716202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05104491 2005-05-25
US69039105P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
TW200716202A true TW200716202A (en) 2007-05-01

Family

ID=35045349

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095118344A TW200716202A (en) 2005-05-25 2006-05-24 Pediatric formulation of topiramate

Country Status (12)

Country Link
US (1) US20060270611A1 (https=)
EP (1) EP1888030A1 (https=)
JP (1) JP2008542237A (https=)
CN (1) CN101257889A (https=)
AR (1) AR053737A1 (https=)
AU (1) AU2006251213A1 (https=)
BR (1) BRPI0610210A2 (https=)
CA (1) CA2609719A1 (https=)
MX (1) MX2007014713A (https=)
RU (1) RU2007148444A (https=)
TW (1) TW200716202A (https=)
WO (1) WO2006125774A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CN104188920A (zh) * 2014-07-28 2014-12-10 安徽省逸欣铭医药科技有限公司 托吡酯颗粒剂及其制备方法
HUE066912T2 (hu) * 2015-08-24 2024-09-28 Zogenix International Ltd Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával
WO2017085687A1 (en) 2015-11-20 2017-05-26 West-Ward Pharmaceuticals International Limited Stable formulation of phenobarbital sodium injection
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
GB2596184A (en) * 2018-09-13 2021-12-22 Ftf Pharma Private Ltd Non-aqueous solutions for oral dosage
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions
GB2594242A (en) * 2020-04-14 2021-10-27 Syri Ltd A stable and ready to administer liquid pharmaceutical composition of topiramate
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN117159458A (zh) * 2022-05-27 2023-12-05 北京万全德众医药生物技术有限公司 托吡酯口服溶液及其制备方法
US12109188B1 (en) * 2023-03-24 2024-10-08 Tap Pharmaceuticals Ag Liquid pharmaceutical formulations of topiramate
US12290504B2 (en) 2023-04-11 2025-05-06 Tap Pharmaceuticals Ag Aqueous formulations of topiramate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出

Also Published As

Publication number Publication date
EP1888030A1 (en) 2008-02-20
BRPI0610210A2 (pt) 2010-06-01
JP2008542237A (ja) 2008-11-27
RU2007148444A (ru) 2009-06-27
MX2007014713A (es) 2008-02-14
AU2006251213A1 (en) 2006-11-30
WO2006125774A1 (en) 2006-11-30
CA2609719A1 (en) 2006-11-30
US20060270611A1 (en) 2006-11-30
CN101257889A (zh) 2008-09-03
AR053737A1 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
TW200716202A (en) Pediatric formulation of topiramate
WO2007044693A3 (en) Multi-functional ionic liquid compositions
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
DK2046292T3 (da) Formuleringer for benzimidazolylpyridylethere
WO2010041141A3 (en) Oil-based foamable carriers and formulations
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
PL1988913T3 (pl) Ciekły preparat G-CSF
UA94065C2 (en) Dihydropseudoerythromycin derivatives
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2010021607A3 (en) Pharmaceutical formulation
WO2004100865A3 (en) New benzimidazole derivatives
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2010029093A3 (en) Compositions for percutaneous administration
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
WO2007121471A3 (en) Dialkyl ether delivery agents
WO2006110810A3 (en) Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
TW200637826A (en) Chemical compounds
CA2547866A1 (en) Farnesyl dibenzodiazepinone formulation
NO20055311L (no) Farmasoytisk aktive ornitinderivater, ammoniumsalter derav og fremgangsmater for fremstilling av det samme
WO2007135295A3 (fr) Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur préparation, compositions les contenant et utilisation